FindTrial
Sign In

Efficacy of intralesional MMR vs BCG in the treatment of multiple warts: A randomized controlled trial

To compare the efficacy of intralesional MMR vs BCG in the treatment of multiple warts: A randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033157
Enrollment
92
Registered
2021-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B070- Plantar wart

Interventions

Intervention1: BCG: The patients will be given BCG at 0,2 and 4 weeks Control Intervention1: MMR: The patients will be given MMR at 0,2 and 4 weeks and the response will be compared with the BCG

Sponsors

Armed Forces Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with multiple warts

Exclusion criteria

Exclusion criteria: Consent denial, pregnancy and lactation, patients who have taken treatment for warts in last 1 month, immunosuppression

Design outcomes

Primary

MeasureTime frame
Reduction in size or number of warts as marked b the patient and dermatologist after 2 weeks, 4 weeks and 6 weeksTimepoint: 2, 4 and 6 weeks from baseline—

Secondary

MeasureTime frame
Clearance of wartsTimepoint: 2,4 and 12 weeks—

Countries

India

Contacts

Public ContactNazir Ahmad Shah

Armed Forces Medical College

bijuvasudevan1975@gmail.com9741290425

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026